Found: 33
Select item for more details and to access through your institution.
Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2020, v. 39, n. 1, p. N.PAG, doi. 10.1186/s13046-020-01723-7
- By:
- Publication type:
- Article
New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 5, p. 4922, doi. 10.3390/ijms24054922
- By:
- Publication type:
- Article
Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 10, p. 912, doi. 10.3390/jcm8070912
- By:
- Publication type:
- Article
Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 7, p. 912, doi. 10.3390/jcm8070912
- By:
- Publication type:
- Article
Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2019, v. 38, n. 1, p. N.PAG, doi. 10.1186/s13046-019-1317-6
- By:
- Publication type:
- Article
Paper-based electrochemical device for early detection of integrin αvβ6 expressing tumors.
- Published in:
- Communications Chemistry, 2024, v. 7, n. 1, p. 1, doi. 10.1038/s42004-024-01144-z
- By:
- Publication type:
- Article
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS -mutated metastatic colorectal cancer: the REVOLUTION study protocol.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920929589
- By:
- Publication type:
- Article
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS -mutated metastatic colorectal cancer: the REVOLUTION study protocol.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, p. 1, doi. 10.1177/1758835920929589
- By:
- Publication type:
- Article
Synthesis and Evaluation of the Antitumor Properties of a Small Collection of PtII Complexes with 7-Deazaadenosine as Scaffold.
- Published in:
- European Journal of Organic Chemistry, 2017, v. 2017, n. 33, p. 4935, doi. 10.1002/ejoc.201700730
- By:
- Publication type:
- Article
Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12936-w
- By:
- Publication type:
- Article
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
- Published in:
- BMC Cancer, 2016, v. 16, p. 1, doi. 10.1186/s12885-016-2957-y
- By:
- Publication type:
- Article
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
- Published in:
- BMC Cancer, 2016, v. 16, p. 1
- By:
- Publication type:
- Article
Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.
- Published in:
- Proteomics, 2011, v. 11, n. 18, p. 3725, doi. 10.1002/pmic.201100092
- By:
- Publication type:
- Article
Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
- Published in:
- Amino Acids, 2017, v. 49, n. 3, p. 517, doi. 10.1007/s00726-016-2338-5
- By:
- Publication type:
- Article
Tissue transglutaminase: a new target to reverse cancer drug resistance.
- Published in:
- Amino Acids, 2013, v. 44, n. 1, p. 63, doi. 10.1007/s00726-011-1167-9
- By:
- Publication type:
- Article
Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood.
- Published in:
- Cytometry. Part A, 2016, v. 89, n. 3, p. 259, doi. 10.1002/cyto.a.22730
- By:
- Publication type:
- Article
HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
- Published in:
- Molecular Oncology, 2021, v. 15, n. 4, p. 1005, doi. 10.1002/1878-0261.12883
- By:
- Publication type:
- Article
Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2017, v. 36, p. 1, doi. 10.1186/s13046-017-0647-5
- By:
- Publication type:
- Article
The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2024, v. 43, n. 1, p. 1, doi. 10.1186/s13046-024-03117-5
- By:
- Publication type:
- Article
Synthesis and Evaluation of the Antiproliferative Properties of a Tethered Tubercidin-Platinum(II) Complex.
- Published in:
- European Journal of Organic Chemistry, 2015, v. 2015, n. 34, p. 7550, doi. 10.1002/ejoc.201500998
- By:
- Publication type:
- Article
Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/α-β catenins complex and multiple erbb receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas.
- Published in:
- Journal of Cellular Physiology, 2012, v. 227, n. 9, p. 3344, doi. 10.1002/jcp.24034
- By:
- Publication type:
- Article
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
- Published in:
- Journal of Cellular Physiology, 2011, v. 226, n. 9, p. 2378, doi. 10.1002/jcp.22574
- By:
- Publication type:
- Article
Critical role of both p27<sup>KIP1</sup>and p21<sup>CIP1/WAF1</sup> in the antiproliferative effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells (Iressa is a trademark of the AstraZeneca group of companies.)
- Published in:
- Journal of Cellular Physiology, 2003, v. 195, n. 1, p. 139, doi. 10.1002/jcp.10239
- By:
- Publication type:
- Article
Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 7, p. e2118475, doi. 10.1001/jamanetworkopen.2021.18475
- By:
- Publication type:
- Article
Plasma metabolomics, lipidomics and cytokinomics profiling predict disease recurrence in metastatic colorectal cancer patients undergoing liver resection.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.1110104
- By:
- Publication type:
- Article
Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02295-4
- By:
- Publication type:
- Article
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02295-4
- By:
- Publication type:
- Article
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02295-4
- By:
- Publication type:
- Article
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
- Published in:
- 2015
- By:
- Publication type:
- journal article
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial).
- Published in:
- BMC Cancer, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2407-14-875
- By:
- Publication type:
- Article
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum 3rd trial).
- Published in:
- BMC Cancer, 2014, v. 14, p. 1, doi. 10.1186/1471-2407-14-875
- By:
- Publication type:
- Article
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).
- Published in:
- 2014
- By:
- Publication type:
- journal article